Published Data Show Why GSK Bailed on Its Maternal RSV Vaccine
GSK’s abandoned maternal respiratory syncytial virus (RSV) vaccine protected infants from severe RSV, final results of a phase III trial indicated, but those positive outcomes came at the expense of an unexplained higher risk for preterm birth. For newborns up to 6 months of age, efficacy with the RSV prefusion F protein-based vaccine (RSVPreF3-Mat) during […]
Respiratory Syncytial Virus (RSV) Definition, Symptoms, Treatment, Transmission
Facts you should know about respiratory syncytial virus (RSV) infection Respiratory Viral Infections RSV is a highly contagious virus infection that is most prevalent during the winter season. Most children who develop an RSV infection have mild symptoms of fever, nasal congestion, nasal discharge, and cough. High-risk groups are more likely to have a more […]
Is Respiratory Syncytial Virus (RSV) Contagious?
Is respiratory syncytial virus (RSV) contagious? Respiratory syncytial virus (RSV) is contagious. In the United States, it’s the most common cause of inflammation of the small airways in the lungs (bronchiolitis) and of pneumonia in children under 1 year of age. It also is significant cause of respiratory illnesses in older adults. Nearly all children […]
RSV Vaccine Benefits Probably Outweigh Small Neurologic Risk, CDC Advisors Say
The benefits of vaccination against respiratory syncytial virus (RSV) for adults ages 60 and older probably outweigh the small risk of vaccine-related Guillain-Barré syndrome (GBS), the CDC’s Advisory Committee on Immunization Practices (ACIP) reaffirmed. In a presentation on the second day of the ACIP’s 2-day meeting, Amadea Britton, MD, of the CDC’s RSV adult vaccination […]
RSV Vaccine Maintains Efficacy Across Two Seasons in Seniors
BOSTON — Efficacy of GSK’s respiratory syncytial virus (RSV) vaccine held strong through two RSV seasons in adults 60 and over, according to new results from the company’s pivotal trial. With a single dose, efficacy of the RSV perfusion F protein vaccine (Arexvy) against RSV-related lower respiratory tract disease declined from 82.6% during the first […]
CDC Advisors Endorse Maternal RSV Vax to Protect Newborns
The CDC’s advisors on Friday recommended a maternal respiratory syncytial virus (RSV) vaccine to protect infants from serious infections. By an 11-1 vote, the Advisory Committee on Immunization Practices (ACIP) recommended that pregnant women receive a single dose of Pfizer’s prefusion F protein (RSVpreF) vaccine (Abrysvo) at 32 to 36 weeks’ gestation to prevent lower […]
What to Know About New Tools to Fight RSV
The tide may be turning on respiratory syncytial virus (RSV), a seasonal scourge that’s responsible for a substantial number of hospitalizations and deaths among older people and young children each year. In the span of just a few months, the FDA has approved two vaccines and a monoclonal antibody for use in specific populations with […]
Second RSV Vaccine Lands Approval for Older Adults
The FDA has approved a second respiratory syncytial virus (RSV) vaccine for preventing lower respiratory infections in adults 60 and over, Pfizer announced on Wednesday. Approval of the unadjuvanted, bivalent RSV prefusion F protein vaccine (Abrysvo) follows an endorsement in March from FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). Advisors voted 7-4 in […]
Safety Data on Maternal RSV Vaccine ‘Favorable,’ FDA Staff Says
A maternal respiratory syncytial virus (RSV) vaccine candidate prevents infections in infants and comes with “generally favorable” safety data, said FDA staff in briefing documents released ahead of an advisory committee meeting this week, but the reviewers “noted potential uncertainty based on the numerical imbalance in premature deliveries.” On Thursday, members of the Vaccines and […]
Second RSV Vaccine for Older Adults Gets Thumbs Up From FDA Advisors
A panel of FDA’s outside advisors recommended the agency approve GSK’s respiratory syncytial virus (RSV) vaccine for older adults, a day after backing Pfizer’s RSV vaccine candidate for that same population. By votes of 12-0 on efficacy and 10-2 on safety, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) said the available data support […]